Adrenocorticotropic Hormone (ACTH) Market Report 2021-2031

Visiongain has published a new report on Adrenocorticotropic Hormone (ACTH) Market Report 2021-2031: Forecasts By Type (AQB-565, BIM-23B065, Corticotropin, Others, By Product (Natural, and Synthetic), By Indication (Nephrotic Syndrome, Ophthalmology, Rheumatology, Addison Disease, Cushing Syndrome, Cushing Disease, and Others), By Age Group (Adult, and Children), By End-User (Hospitals, Specialty Clinics, Academics and Research Institute, and Others), By Distribution Channel (Hospital Pharmacy, and Retail Pharmacy, and Online Pharmacy). PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

COVID-19 Impact on Adrenocorticotropic Hormone (ACTH) Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Adrenocorticotropic Hormone (ACTH) market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Increasing usage of Adrenocorticotropic Hormone products
The application of adrenocorticotropic hormone (ACTH) has increased very significantly over the past few years. Currently, the adrenocorticotropic hormone is administered for the treatment of nephrotic syndrome, ophthalmology, rheumatology, Addison disease, Cushing syndrome, Cushing disease, and others. The increase in the usage of adrenocorticotropic hormone products is creating a huge demand for the adrenocorticotropic hormone (ACTH) products and working as a driver for the market.

Market Opportunities

Government initiative and awareness program
Governments in various developed and developing nations are increasing their initiatives to increasing awareness regarding the availability of treatment for nephrotic syndrome, ophthalmology, rheumatology, Addison disease, Cushing syndrome, Cushing disease, and others. Further, Governments and private authority across the developed & developing countries are focusing on the increasing number of new approval for adrenocorticotropic hormone (ACTH) which will help to create new opportunities for the market.

Technological Advancements and the modernization in Adrenocorticotropic Hormone (ACTH)
Researchers and manufacturers from all over the world are increasing research and development activates for the development of new, innovative, more effective, economic and to increase the clinical application of adrenocorticotropic hormone (ACTH). New research and development will lead to the introduction of new products in the market which is expected to increase the adoption of adrenocorticotropic hormone (ACTH).

Competitive Landscape
Top companies (Mallinckrodt, Pfizer, Novartis AG,) constitute more than XX% share of the global Adrenocorticotropic Hormone (ACTH) market. Other companies profiled in the report include Mylan N.V., and Hikma Pharmaceuticals Others Some of the key developments are listed below:

• In 2018, Mallinckrodt ARD Inc. has received U.S. FDA approval for H.P. Acthar Ge. H.P. Acthar Ge is an adrenocorticotropic hormone (ACTH) analog indicated as monotherapy for infantile spasms treatment in infants. Through this development company will widen its market-focused product portfolio.

Find more research reports on pharmaceutical Industry, by Visiongain:

• Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031
• Women’s Health Diagnostics Market Report to 2031
• Animal Model Market Report to 2031
  
  

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent market research and consulting company in Europe. Based in London, UK, the company comprises over 400+ analysts and consultants, adding more than 1400 market research reports to its vast database each year. These reports offer in-depth analysis on 18 industries worldwide. With the help of an interactive market intelligence platform, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Contact:

Sara Peerun
Commercial Director
Visiongain Limited
Phone: +44 (0) 20 7549 9987.
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter

SOURCE Visiongain Ltd.